Amundi Raises Position in Moderna, Inc. $MRNA

Amundi increased its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 10.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,335,290 shares of the company's stock after acquiring an additional 129,017 shares during the period. Amundi owned about 0.35% of Moderna worth $37,855,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of MRNA. S Bank Fund Management Ltd bought a new stake in shares of Moderna in the first quarter worth $25,000. SVB Wealth LLC bought a new stake in shares of Moderna in the first quarter worth $28,000. Costello Asset Management INC bought a new stake in shares of Moderna in the first quarter worth $30,000. Sentry Investment Management LLC bought a new stake in shares of Moderna in the first quarter worth $31,000. Finally, Deseret Mutual Benefit Administrators grew its holdings in shares of Moderna by 53.3% in the first quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock worth $32,000 after acquiring an additional 392 shares during the period. Institutional investors own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on MRNA. Citigroup began coverage on Moderna in a report on Friday, August 1st. They set a "neutral" rating and a $40.00 price target for the company. Morgan Stanley reissued an "equal weight" rating and set a $32.00 price target on shares of Moderna in a report on Friday, August 1st. Barclays cut their price target on Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a report on Monday, August 4th. William Blair reissued a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. Finally, Cowen began coverage on Moderna in a report on Sunday, July 13th. They set a "hold" rating for the company. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, sixteen have issued a Hold rating and four have given a Sell rating to the company's stock. According to MarketBeat.com, Moderna presently has an average rating of "Hold" and an average price target of $42.88.

Moderna Stock Down 7.5%

Moderna stock traded down $1.91 during midday trading on Friday, reaching $23.48. 12,169,070 shares of the stock traded hands, compared to its average volume of 10,700,715. The stock's fifty day moving average is $28.48 and its 200-day moving average is $28.28. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $75.37. The stock has a market cap of $9.14 billion, a P/E ratio of -3.12 and a beta of 1.93.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The company had revenue of $142.00 million during the quarter, compared to analyst estimates of $116.26 million. During the same period in the prior year, the company earned ($3.33) earnings per share. The firm's revenue was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. On average, equities analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.